(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for units totalling aggregate gross proceeds of approximately CAD1.82 million and had closed on CAD1.58 million.
- 0 Comments
- FY2017